COVID-19 update, 20 Mar

Drug combination works in hospitalized patients!

A small French study shows that an old malaria drug, hydroxychloroquine (HCQ) combined with (AZ) azithromycin.

The graph below shows the percent of patients with a nasal swab that contains the virus.

Black line (control), no change over six days.

Blue line, HCQ alone, nice reduction that is different from control on day 3 but is not cured by day six.

Green line, HCQ plus AZ together, better reduction than HCQ alone and NO VIRUS by day 5!

Caveat: a 20 patient study so results may differ on a big scale but this is a major breakthrough.

Note: my previous analysis of HCQ based on test tube data was that it would fail. I am glad it was tested!

Here is the paper if you want details.

About Dr. Quay

Steven Quay is the CEO of Atossa Therapeutics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and COVID-19. He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 200,000 times. His 300+ contributions to medicine have been cited over 9,900 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people.

The COVID-19 HOPE Clinical Trial​